Impact of Practice-Based Management of Pulmonary Artery Pressures in 2000 Patients Implanted With the CardioMEMS Sensor

Background: Elevated pulmonary artery (PA) pressures in patients with heart failure are associated with a high risk for hospitalization and mortality. Recent clinical trial evidence demonstrated a direct relationship between lowering remotely monitored PA pressures and heart failure hospitalization risk reduction with a novel implantable PA pressure monitoring system (CardioMEMS HF System, St. Jude Medical). This study examines PA pressure changes in the first 2000 US patients implanted in general practice use. Methods: Deidentified data from the remote monitoring Merlin.net (St. Jude Medical) database were used to examine PA pressure trends from the first consecutive 2000 patients with at least 6 months of follow-up. Changes in PA pressures were evaluated with an area under the curve methodology to estimate the total sum increase or decrease in pressures (mm Hg-day) during the follow-up period relative to the baseline pressure. As a reference, the PA pressure trends were compared with the historic CHAMPION clinical trial (CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in New York Heart Association [NYHA] Functional Class III Heart Failure Patients). The area under the curve results are presented as mean±2 SE, and P values comparing the area under the curve of the general-use cohort with outcomes in the CHAMPION trial were computed by the t test with equal variance. Results: Patients were on average 70±12 years old; 60% were male; 34% had preserved ejection fraction; and patients were followed up for an average of 333±125 days. At implantation, the mean PA pressure for the general-use patients was 34.9±10.2 mm Hg compared with 31.3±10.9 mm Hg for CHAMPION treatment and 32.0±10.5 mm Hg for CHAMPION control groups. The general-use patients had an area under the curve of −32.8 mm Hg-day at the 1-month time mark, −156.2 mm Hg-day at the 3-month time mark, and −434.0 mm Hg-day after 6 months of hemodynamic guided care, which was significantly lower than the treatment group in the CHAMPION trial. Patients consistently transmitted pressure information with a median of 1.27 days between transmissions after 6 months. Conclusions: The first 2000 general-use patients managed with hemodynamic-guided heart failure care had higher PA pressures at baseline and experienced greater reduction in PA pressure over time compared with the pivotal CHAMPION clinical trial. These data demonstrate that general use of implantable hemodynamic technology in a nontrial setting leads to significant lowering of PA pressures.

[1]  M. Zile,et al.  Chronic Ambulatory Intracardiac Pressures and Future Heart Failure Events , 2010, Circulation. Heart failure.

[2]  G. Ogedegbe,et al.  Heart failure–associated hospitalizations in the United States. , 2013, Journal of the American College of Cardiology.

[3]  Mark D. Huffman,et al.  Heart Disease and Stroke Statistics—2016 Update: A Report From the American Heart Association , 2016, Circulation.

[4]  M. Gheorghiade,et al.  The worst symptom as defined by patients during heart failure hospitalization: implications for response to therapy. , 2012, Journal of cardiac failure.

[5]  R. Benza,et al.  Pulmonary hypertension related to left heart disease: insight from a wireless implantable hemodynamic monitor. , 2015, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[6]  S. Anker,et al.  Remote haemodynamic‐guided care for patients with chronic heart failure: a meta‐analysis of completed trials , 2017, European journal of heart failure.

[7]  M. Metra,et al.  The pathophysiology of acute heart failure--it is a lot about fluid accumulation. , 2008, American heart journal.

[8]  L. Rydén,et al.  Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system. , 2003, Journal of the American College of Cardiology.

[9]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[10]  G. Filippatos,et al.  Congestion in acute heart failure syndromes: an essential target of evaluation and treatment. , 2006, The American journal of medicine.

[11]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[12]  Wojciech Zareba,et al.  Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. , 2002, The New England journal of medicine.

[13]  B. Dawson-Hughes,et al.  Preventing osteoporosis-related fractures: an overview. , 2006, The American journal of medicine.

[14]  William T. Abraham,et al.  Wireless Pulmonary Artery Pressure Monitoring Guides Management to Reduce Decompensation in Heart Failure With Preserved Ejection Fraction , 2014, Circulation. Heart failure.

[15]  M. Zile,et al.  Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study. , 2008, Journal of the American College of Cardiology.

[16]  M. Zile,et al.  Intracardiac Pressures Measured Using an Implantable Hemodynamic Monitor: Relationship to Mortality in Patients With Chronic Heart Failure. , 2017, Circulation. Heart failure.

[17]  M. Borggrefe,et al.  Intrathoracic Impedance Monitoring, Audible Patient Alerts, and Outcome in Patients With Heart Failure , 2011, Circulation.

[18]  A. Rigby,et al.  Noninvasive home telemonitoring for patients with heart failure at high risk of recurrent admission and death: the Trans-European Network-Home-Care Management System (TEN-HMS) study. , 2005, Journal of the American College of Cardiology.

[19]  Michael Böhm,et al.  Impact of Remote Telemedical Management on Mortality and Hospitalizations in Ambulatory Patients With Chronic Heart Failure: The Telemedical Interventional Monitoring in Heart Failure Study , 2011, Circulation.

[20]  F. Martinez,et al.  Heart failure and respiratory hospitalizations are reduced in patients with heart failure and chronic obstructive pulmonary disease with the use of an implantable pulmonary artery pressure monitoring device. , 2015, Journal of cardiac failure.

[21]  Christopher M O'Connor,et al.  The pathophysiology of acute heart failure--is it all about fluid accumulation? , 2008, American heart journal.

[22]  M. Zile,et al.  Transition From Chronic Compensated to Acute Decompensated Heart Failure: Pathophysiological Insights Obtained From Continuous Monitoring of Intracardiac Pressures , 2008, Circulation.

[23]  P A Poole-Wilson,et al.  Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. , 1999, Circulation.

[24]  Robert A McNutt,et al.  Decompensated heart failure: symptoms, patterns of onset, and contributing factors. , 2003, The American journal of medicine.

[25]  J. Cohn,et al.  A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. , 2001, The New England journal of medicine.

[26]  M. Pfeffer,et al.  Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.

[27]  J. Daubert,et al.  The effect of cardiac resynchronization on morbidity and mortality in heart failure. , 2005, The New England journal of medicine.

[28]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[29]  J. Oss,et al.  PROPHYLACTIC IMPLANTATION OF A DEFIBRILLATOR IN PATIENTS WITH MYOCARDIAL INFARCTION AND REDUCED EJECTION FRACTION , 2002 .

[30]  S. Schneeweiss,et al.  Repeated hospitalizations predict mortality in the community population with heart failure. , 2007, American heart journal.

[31]  Douglas L Packer,et al.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.

[32]  M. Drazner,et al.  Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. , 2001, The New England journal of medicine.

[33]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[34]  Bristow Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) : Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure , 2004 .

[35]  Majid Sarrafzadeh,et al.  Effectiveness of Remote Patient Monitoring After Discharge of Hospitalized Patients With Heart Failure: The Better Effectiveness After Transition -- Heart Failure (BEAT-HF) Randomized Clinical Trial. , 2016, JAMA internal medicine.

[36]  P. Adamson,et al.  Pathophysiology of the transition from chronic compensated and acute decompensated heart failure: New insights from continuous monitoring devices , 2009, Current heart failure reports.

[37]  Naoki Sato,et al.  The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. , 2014, Journal of the American College of Cardiology.

[38]  Volkmar Falk,et al.  2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. , 2016, Revista espanola de cardiologia.

[39]  Akshay S. Desai,et al.  Pulmonary Artery Pressure–Guided Heart Failure Management Reduces 30-Day Readmissions , 2016, Circulation. Heart failure.

[40]  A. Little,et al.  American Heart Association: Council on Arteriosclerosis , 1960 .

[41]  M. Gheorghiade,et al.  Fluid overload in acute heart failure — Re‐distribution and other mechanisms beyond fluid accumulation , 2008, European journal of heart failure.

[42]  D. DeMets,et al.  Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.

[43]  L. Stevenson,et al.  Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial , 2016, The Lancet.

[44]  William T. Abraham,et al.  Physician-Directed Patient Self-Management of Left Atrial Pressure in Advanced Chronic Heart Failure , 2010, Circulation.

[45]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[46]  J. Cohn,et al.  Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. , 2002, Journal of the American College of Cardiology.

[47]  L. Stevenson,et al.  CHAMPION trial rationale and design: the long-term safety and clinical efficacy of a wireless pulmonary artery pressure monitoring system. , 2011, Journal of cardiac failure.

[48]  D. DeMets,et al.  Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. , 2004, The New England journal of medicine.

[49]  I. Piña,et al.  Forecasting the Impact of Heart Failure in the United States: A Policy Statement From the American Heart Association , 2013, Circulation. Heart failure.

[50]  Ayesha Hasan,et al.  Safety and accuracy of a wireless pulmonary artery pressure monitoring system in patients with heart failure. , 2011, American heart journal.

[51]  Fred C Tenover,et al.  Mechanisms of antimicrobial resistance in bacteria. , 2006, The American journal of medicine.

[52]  Volkmar Falk,et al.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016, Revista espanola de cardiologia.

[53]  T. Nakata,et al.  Clinical implications of midventricular obstruction and intravenous propranolol use in transient left ventricular apical ballooning (Tako-tsubo cardiomyopathy). , 2008, American heart journal.

[54]  H. Krumholz,et al.  Telemonitoring in patients with heart failure. , 2010, The New England journal of medicine.

[55]  L. Stevenson,et al.  Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial , 2011, The Lancet.

[56]  Akshay S. Desai,et al.  Interventions Linked to Decreased Heart Failure Hospitalizations During Ambulatory Pulmonary Artery Pressure Monitoring. , 2016, JACC. Heart failure.